Scarica l'app Stockscreener
90.78
2.33%
-2.17
Dopo l'orario di chiusura:
90.50
-0.28
-0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Swiss Life Asset Management Ltd Increases Stake in Incyte Corporation $INCY - MarketBeat
New England Research & Management Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
INCY wins EC approval for label expansion of oncology drug Zynyz - MSN
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data a - The National Law Review
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - The AI Journal
Is Incyte Stock Outperforming the Dow? - Barchart.com
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma - openPR.com
Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma Companies Advance Novel Skin Cancer Therapies, Finds DelveInsight | Incyte, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Roche, G - Barchart.com
Incyte (NASDAQ:INCY) Insider Sells 18,667 Shares - MarketBeat
Incyte president Pablo Cagnoni sells $1.76 million in stock - Investing.com
Incyte (NASDAQ: INCY) R&D head exercises options, sells 18,667 shares - Stock Titan
Incyte Corp Stock (ISIN: US45337C1027) Faces Pressure Amid Oncology Pipeline Setbacks and Market Vol - AD HOC NEWS
Incyte (INCY) Downgraded by Jefferies; Price Target Lowered | IN - GuruFocus
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Faithward Advisors LLC Takes $4.45 Million Position in Incyte Corporation $INCY - MarketBeat
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte’s Latin American MINJUVI Steps Expand Oncology Story Beyond Jakafi - Yahoo Finance
Incyte (INCY) Strengthens Partnership with Knight for MINJUVI in Latin America - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Form 144: INCY (NASDAQ: INCY) reports 18,667-share stock option sale - Stock Titan
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue (NASDAQ:INCY) - Seeking Alpha
How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story - simplywall.st
Jefferies downgrades Incyte stock rating on patent cliff concerns - Investing.com
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment - MyChesCo
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer - Yahoo Finance
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
INCYIncyte Corp Stock Price and Quote - Finviz
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication - RTTNews
Mackenzie Financial Corp Has $38.43 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
WINTON GROUP Ltd Acquires 213,557 Shares of Incyte Corporation $INCY - MarketBeat
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts - Benzinga
INCY: Today's Analyst Rating Update by HC Wainwright & Co. | INC - GuruFocus
Incyte wins EC approval of Zynyz for SCAC - The Pharmaletter
Meiji Yasuda Asset Management Co Ltd. Has $2.34 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - BioSpace
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):